Showing results (1-10 of 164) with videos related to
Sort By:
Pageof 17
Frontiers in Neuroscience|December 31, 2020
Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's DiseaseNiklas Reich, Christian HölscherFrontiers in Neuroscience|September 19, 2022
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth reviewNiklas Reich, Christian HölscherNeuroscience and Biobehavioral Reviews|November 11, 2022
Beyond appetite: Acylated ghrelin as a learning, memory and fear behavior-modulating hormoneNiklas Reich, Christian HölscherFrontiers in Neuroendocrinology|February 12, 2024
Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer's and Parkinson's diseaseNiklas Reich, Christian HölscherAlzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 18, 2014
The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's diseaseChristian HölscherBiochemical Society Transactions|July 27, 2011
Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's diseaseChristian HölscherThe Journal of Endocrinology|September 4, 2013
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseasesChristian HölscherSheng Li Xue Bao : [Acta Physiologica Sinica]|October 22, 2014
Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseasesChristian HölscherFrontiers in Synaptic Neuroscience|August 15, 2022
Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer's and Parkinson's diseasesChristian HölscherBiochemical Society Transactions|March 21, 2014
Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseasesChristian HölscherPageof 17